• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities
【24h】

Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities

机译：使用工程化细胞因子信号和其他方式增强养老细胞免疫疗法的策略

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Cancer therapy has been transformed by the demonstration that tumor-specific T-cells can eliminate tumor cells in a clinical setting with minimal long-term toxicity. However, significant success in the treatment of leukemia and lymphoma with T-cells using native receptors or redirected with chimeric antigen receptors (CARs) has not been recapitulated in the treatment of solid tumors. This lack of success is likely related to the paucity of costimulatory and cytokine signaling available in solid tumors, in addition to a range of inhibitory mechanisms. Areas covered: We summarize the latest developments in engineered T-cell immunotherapy, describe the limitations of these approaches in treating solid tumors, and finally highlight several strategies that may be useful in mediating solid tumor responses in the future, while also ensuring safety of engineered cells. Expert opinion: CAR-T therapies require further engineering to achieve their potential against solid tumors. Facilitating cytokine signaling in CAR T-cells appears to be essential in achieving better responses. However, the engineering of T-cells with potentially unchecked proliferation and potency raises the question of whether the simultaneous combination of enhancements will prove safe, necessitating continued advancements in regulating CAR-T activity at the tumor site and methods to safely switch off these engineered cells.
机译：介绍：癌症治疗已经通过演示转化，即肿瘤特异性T细胞可以以最小的长期毒性消除临床环境中的肿瘤细胞。然而，在使用天然受体或用嵌合抗原受体（汽车）的治疗或通过用嵌合抗原受体（CARS）进行重新定向的T细胞治疗白血病和淋巴瘤的显着成功尚未在治疗实体肿瘤的情况下重新携带。除了一系列抑制机制外，这种缺乏成功可能与实体瘤中可用的共同刺激和细胞因子信号的缺乏有关。所涵盖的地区：总结了工程化T细胞免疫疗法的最新发展，描述了这些方法治疗实体肿瘤的局限性，最终突出了几种可能在未来介导实体瘤反应的策略，同时也确保了工程的安全性细胞。专家意见：Car-T疗法需要进一步的工程来实现它们对固体肿瘤的潜力。在汽车T细胞中促进细胞因子信号似乎是实现更好反应的必要条件。然而，具有潜在未经检查的增殖和效力的T细胞的工程提出了增强功能同时组合的问题，需要安全，需要在肿瘤部位和安全地关闭这些工程细胞的方法中调节Car-T活性的持续进步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号